Alnylam Pharmaceuticals I... (ALNY)
NASDAQ: ALNY
· Real-Time Price · USD
462.10
-5.45 (-1.17%)
At close: Aug 22, 2025, 10:43 AM
-1.17% (1D)
| Bid | 427.09 |
| Market Cap | 60.57B |
| Revenue (ttm) | 2.46B |
| Net Income (ttm) | -319.09M |
| EPS (ttm) | -2.47 |
| PE Ratio (ttm) | -187.08 |
| Forward PE | 79.43 |
| Analyst | Buy |
| Ask | 504.24 |
| Volume | 168,916 |
| Avg. Volume (20D) | 1,238,403.1 |
| Open | 469.17 |
| Previous Close | 467.55 |
| Day's Range | 460.10 - 469.81 |
| 52-Week Range | 205.87 - 469.99 |
| Beta | 0.25 |
About ALNY
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALNY
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALNY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Alnylam Pharmaceuticals Inc. is scheduled to release its earnings on
Oct 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+4.42%
Alnylam Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
3 weeks ago
+15.43%
Alnylam Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance above estimates.
3 weeks ago · seekingalpha.com
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call TranscriptAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Christine Regan Akinc - Chief Corporate Communications Officer Jeffrey V. Po...
